Literature DB >> 21448425

Strong expression of CD133 is associated with increased cholangiocarcinoma progression.

Kawin Leelawat1, Taweesak Thongtawee, Siriluck Narong, Somboon Subwongcharoen, Sa-ad Treepongkaruna.   

Abstract

AIM: To determine the role of CD133 in cholangiocarcinoma progression.
METHODS: CD133 protein expression was evaluated by immunohistochemistry in 34 cholangiocarcinoma specimens. In addition, proliferation, chemoresistance and invasive properties of CD133-enriched (CD133(+)) and CD133-depleted (CD133(-)) RMCCA1 cholangiocarcinoma cells were studied and compared.
RESULTS: Strong CD133 expression was observed in 67.6% (23/34) of the cholangiocarcinoma specimens. Strong expression of CD133 was significantly associated with nodal metastasis (P = 0.009) and positive surgical margin status (P = 0.011). In the in vitro study, both the CD133(+) and CD133(-) cells had similar proliferation abilities and resistance to chemotherapeutic drugs. However, the CD133(+) cells had a higher invasive ability compared with CD133(-) cells.
CONCLUSION: CD133+ cells play an important role in the invasiveness of cholangiocarcinoma. Targeting of the CD133+ cells may be a useful approach to improve treatment against cholangiocarcinoma.

Entities:  

Keywords:  CD133; Cholangiocarcinoma; Immunohistochemistry; Invasion; Metastasis

Mesh:

Substances:

Year:  2011        PMID: 21448425      PMCID: PMC3063913          DOI: 10.3748/wjg.v17.i9.1192

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  18 in total

1.  Study on the proliferation and drug-resistance of human brain tumor stem-like cells.

Authors:  Kun Qin; Xiaodan Jiang; Yuxi Zou; Jianqi Wang; Lingsha Qin; Yanjun Zeng
Journal:  Cell Mol Neurobiol       Date:  2010-06-06       Impact factor: 5.046

Review 2.  Colon cancer stem cells: promise of targeted therapy.

Authors:  Matilde Todaro; Maria Giovanna Francipane; Jan Paul Medema; Giorgio Stassi
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

3.  Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.

Authors:  Wei Ding; Hanning You; Hien Dang; Francis LeBlanc; Vivian Galicia; Shelly C Lu; Bangyan Stiles; C Bart Rountree
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Authors:  Panthip Rattanasinganchan; Kawin Leelawat; Sa-ard Treepongkaruna; Chintana Tocharoentanaphol; Somboon Subwongcharoen; Tuangporn Suthiphongchai; Rutaiwan Tohtong
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 5.  Proximal biliary malignancy.

Authors:  Mohamed Akoad; Roger Jenkins
Journal:  Surg Clin North Am       Date:  2008-12       Impact factor: 2.741

6.  Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.

Authors:  W Song; H Li; K Tao; R Li; Z Song; Q Zhao; F Zhang; K Dou
Journal:  Int J Clin Pract       Date:  2008-05-08       Impact factor: 2.503

Review 7.  CD133: molecule of the moment.

Authors:  D Mizrak; M Brittan; M R Alison
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 8.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

9.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

10.  Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells.

Authors:  Kawin Leelawat; Siriluck Narong; Wandee Udomchaiprasertkul; Surang Leelawat; Sumalee Tungpradubkul
Journal:  Cancer Cell Int       Date:  2009-01-08       Impact factor: 5.722

View more
  13 in total

1.  Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.

Authors:  Xia Chu; Po Zhao; Yali Lv; Lin Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Profiles of cancer stem cell subpopulations in cholangiocarcinomas.

Authors:  Vincenzo Cardinale; Anastasia Renzi; Guido Carpino; Alessia Torrice; Maria C Bragazzi; Felice Giuliante; Agostino M DeRose; Alice Fraveto; Paolo Onori; Chiara Napoletano; Antonio Franchitto; Alfredo Cantafora; GianLuca Grazi; Nicola Caporaso; Giuseppe D'Argenio; Gianfranco Alpini; Lola M Reid; Eugenio Gaudio; Domenico Alvaro
Journal:  Am J Pathol       Date:  2015-04-17       Impact factor: 4.307

3.  Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma.

Authors:  P O Zhao; Xiaoying Li; Yali Lu; Lin Liu
Journal:  Oncol Lett       Date:  2015-06-03       Impact factor: 2.967

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

5.  Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.

Authors:  Kai-Chao Feng; Ye-Lei Guo; Yang Liu; Han-Ren Dai; Yao Wang; Hai-Yan Lv; Jian-Hua Huang; Qing-Ming Yang; Wei-Dong Han
Journal:  J Hematol Oncol       Date:  2017-01-05       Impact factor: 17.388

6.  CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma.

Authors:  Xiaobo Cai; Jun Li; Xiaodong Yuan; Jingbo Xiao; Steven Dooley; Xinjian Wan; Honglei Weng; Lungen Lu
Journal:  J Transl Med       Date:  2018-03-06       Impact factor: 5.531

7.  Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer.

Authors:  Tatsuzo Mizukami; Hirofumi Kamachi; Tomoko Mitsuhashi; Takahiro Einama; Yutaka Hatanaka; Toshiya Kamiyama; Akinobu Taketomi
Journal:  Oncol Lett       Date:  2018-09-25       Impact factor: 2.967

8.  A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma.

Authors:  Ding-Zhong Peng; Jiong Lu; Bei Li; Hai-Jie Hu; Xi-Wen Ye; Xian-Ze Xiong; Nan-Sheng Cheng
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-04-21

9.  Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.

Authors:  Jiliang Feng; Dawei Zhao; Fudong Lv; Zhongyu Yuan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

Review 10.  New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.

Authors:  Maria Consiglia Bragazzi; Lorenzo Ridola; Samira Safarikia; Sabina Di Matteo; Daniele Costantini; Lorenzo Nevi; Vincenzo Cardinale
Journal:  Ann Gastroenterol       Date:  2017-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.